KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2016 - 2025)

Jazz Pharmaceuticals has reported Accumulated Expenses over the past 16 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly results put Accumulated Expenses at $1.0 billion for Q4 2025, up 13.53% from a year ago — trailing twelve months through Dec 2025 was $1.0 billion (up 13.53% YoY), and the annual figure for FY2025 was $1.0 billion, up 13.53%.
  • Accumulated Expenses for Q4 2025 was $1.0 billion at Jazz Pharmaceuticals, up from $1.0 billion in the prior quarter.
  • Over the last five years, Accumulated Expenses for JAZZ hit a ceiling of $1.1 billion in Q1 2025 and a floor of $374.0 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $781.9 million (2023), compared with a mean of $763.5 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 110.21% in 2021 and later dropped 1.16% in 2023.
  • Jazz Pharmaceuticals' Accumulated Expenses stood at $666.3 million in 2021, then rose by 20.55% to $803.3 million in 2022, then fell by 1.16% to $793.9 million in 2023, then rose by 14.74% to $910.9 million in 2024, then increased by 13.53% to $1.0 billion in 2025.
  • The last three reported values for Accumulated Expenses were $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $874.8 million (Q2 2025) per Business Quant data.